PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-50.43%
Negative net income growth while CRVO stands at 38.84%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
7.46%
Some D&A expansion while CRVO is negative at -25.57%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
46.91%
Deferred tax of 46.91% while CRVO is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
9.40%
SBC growth while CRVO is negative at -14.06%. John Neff would see competitor possibly controlling share issuance more tightly.
-262.74%
Both reduce yoy usage, with CRVO at -146.65%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-225.01%
Both negative yoy AP, with CRVO at -155.36%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
155.76%
Growth well above CRVO's 218.25%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
9.40%
Lower 'other non-cash' growth vs. CRVO's 89.45%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
-30.81%
Negative yoy CFO while CRVO is 38.25%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
49.68%
CapEx growth well above CRVO's 83.10%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Purchases growth of 100.00% while CRVO is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Growth of 100.00% while CRVO is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
82.07%
We have mild expansions while CRVO is negative at -100.00%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
-1.11%
We cut debt repayment yoy while CRVO is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
207.88%
Issuance growth of 207.88% while CRVO is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.